April 1997

In the article "Scientists Debate RNA's Role At Beginning Of Life On Earth" (R. Lewis, The Scientist, March 31, 1997, page 11), an incorrect affiliation was given for Carl Woese. He is at the University of Illinois, Urbana-Champaign. In the Hot Paper feature in the Feb. 17, 1997, issue of The Scientist (page 16), Chris Schindler, an assistant professor of medicine and physiology at Columbia University, should have been noted as a senior author of M. Azam et al., EMBO Journal, 14:1402-11, 1995.

For two decades, disparagement of science has been among the products of an emerging academic multidiscipline-"science studies," or "sci-tech-studies" (STS) as it's known in the United States. Only recently has serious notice been taken, by a few scientists and other scholars, of the phenomenon. The general agreements and normal academic food-fights within STS have received little outside attention. Not all STS participants, by any means, disparage science. Good work is being done in the socia

Readers of The Scientist by now should be familiar with the aims of Research!America, the Alexandria, Va.-based national nonprofit advocacy organization for biomedical research that was founded in 1989. Chairing its annual membership meeting on March 12, former Congressman Paul Rogers discussed the remarkable progress Research!America has made in advancing the cause of biomedical research. Mary Woolley, the organization's president, reported on the public's increased awareness of the need for g

We concur with the letter appearing in The Scientist, Feb. 17, 1997, by H. Hugh Fudenberg [page 13], which states that potentially effective alternative HIV therapies exist today and are attracting interest and undergoing active investigation. These alternative therapies have not been given fair consideration in comparison to the exploitation of pharmaceuticals. In the past, the proclamation that AZT would revolutionize the treatment of this life-threatening illness and provide a possible cure

Further to the letter by H.H. Fudenberg appearing in The Scientist of Feb. 17, 1997 [page 13], we would like to point out that, although we agree with his overall contention regarding the beneficial effects of transfer factor even on advanced-stage AIDS patients, our polymerase chain reaction (PCR) data, albeit limited, do not confirm his equally limited observations, suggesting a dramatic drop in the PCR counts. In our experience, only one out of three patients showed an important decrease in

In reference to my previous letter published in The Scientist (Feb. 17, 1997, page 13), the implication in my text that polymerase chain reaction (PCR) results obtained by my colleagues Dimitri Viza and Giancarlo Pizza confirm mine was erroneous. My letter should have stated that Viza and Pizza also obtained promising results in AIDS. For instance, all nine AIDS patients treated with HIV-specific transfer factor (TF) who were anergic (negative) to the six common skin test antigens developed de

Here are a few grant-writing rules to remember, according to National Institutes of Health reviewers and staff: check NIH's Web site for information on grant policy; call program staff ahead of time to learn what's hot-and what's not; ask colleagues to critique your grant application before submission; keep research goals simple and clear; carefully follow reviewers' suggestions for revisions when your grant application is returned. promise the world in one lab project; stack a grant ap

Sidebar: The Dos and Don'ts of Winning Dollars Sidebar: Grant Writing - For More Information A NEW STRATEGY: UC-Irvine’s Keith Woerpel, who revised his rejected grant applications to focus on impact, now has several grants. To Keith Woerpel, 1994 will forever be the year he learned to write grants-the hard way. An assistant professor of chemistry at the University of California, Irvine, Woerpel wrote five grant applications that year. All were rejected. "I was getting burned really badly

Grant Writing - More Information Date: April 28, 1997 FOR MORE INFORMATION NIH Division of Research Grants http://www.drg.nih.gov Biomedical Grants on the Internet http://www.biomed.lib.umn.edu/grantstext.html Ellen Barrett's Hints for Writing Successful NIH Grants http://chroma.med.miami.edu/research/Ellens_how_to.html Who's Who In Federal Grants Management http://www.os.dhhs.gov/progorg/grantsnet/whoswho.html

NUMEROUS APPLICATIONS: Bio-Tek Instruments' FL600 automated fluorescence microplate reader tells the researcher how many living cells are in a bacterial culture. In the natural world, microorganisms wear many hats. They are agents of disease, producers of proteins, remediators of rubbage, and brewers of beer. The field of microbiology is just as diverse. A microbiologist may search for ways to inhibit bacterial growth or for methods to make bacteria grow faster. Scientists may coax bacteria to

Monoclonal Antibody Production System: The Cell-Pharm System 100 is designed for research-scale production of monoclonal antibodies, viruses, and recombinant proteins in a benchtop operation. It is intended for laboratories that screen cell lines in feasibility programs or scale up operations of biomolecules. Using hollow fiber bioreactor technology, the system is capable of producing 50 mg to 250 mg of antibodies in a month, according to the company, while eliminating concentration steps as

Twenty-five years after the notorious Tuskegee study came to light, the United States government will formally apologize to its unwitting participants. The White House announced in early April that President Clinton soon would issue an apology to the 399 African American men whose syphilis was observed from 1932 to 1972 as part of an experiment by the U.S. Public Health Service. Despite the discovery in 1947 that penicillin cures syphilis, researchers neither treated the men nor told them they